KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Boston Scientific (BSX) Share-based Compensation (2016 - 2025)

Boston Scientific's Share-based Compensation history spans 17 years, with the latest figure at $71.0 million for Q4 2025.

  • For Q4 2025, Share-based Compensation rose 2.9% year-over-year to $71.0 million; the TTM value through Dec 2025 reached $299.0 million, up 12.41%, while the annual FY2025 figure was $299.0 million, 12.41% up from the prior year.
  • Share-based Compensation for Q4 2025 was $71.0 million at Boston Scientific, down from $79.0 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $79.0 million in Q3 2025 and bottomed at $47.0 million in Q1 2021.
  • The 5-year median for Share-based Compensation is $59.0 million (2023), against an average of $60.6 million.
  • The largest annual shift saw Share-based Compensation grew 27.5% in 2021 before it increased 1.72% in 2023.
  • A 5-year view of Share-based Compensation shows it stood at $49.0 million in 2021, then rose by 12.24% to $55.0 million in 2022, then grew by 7.27% to $59.0 million in 2023, then increased by 16.95% to $69.0 million in 2024, then rose by 2.9% to $71.0 million in 2025.
  • Per Business Quant, the three most recent readings for BSX's Share-based Compensation are $71.0 million (Q4 2025), $79.0 million (Q3 2025), and $75.0 million (Q2 2025).